{"created":"2023-07-27T06:55:15.620929+00:00","id":51026,"links":{},"metadata":{"_buckets":{"deposit":"dd241b53-a8cb-468c-a904-81dce5170960"},"_deposit":{"created_by":18,"id":"51026","owners":[18],"pid":{"revision_id":0,"type":"depid","value":"51026"},"status":"published"},"_oai":{"id":"oai:kanazawa-u.repo.nii.ac.jp:00051026","sets":["2812:2813:2832"]},"author_link":["92398","20052"],"item_9_biblio_info_8":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2002-03","bibliographicIssueDateType":"Issued"},"bibliographicPageStart":"44p.","bibliographicVolumeNumber":"2000-2001","bibliographic_titles":[{"bibliographic_title":"平成13(2001)年度 科学研究費補助金 基盤研究(C) 研究成果報告書"},{"bibliographic_title":"2001 Fiscal Year Final Research Report","bibliographic_titleLang":"en"}]}]},"item_9_creator_33":{"attribute_name":"著者別表示","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{}],"nameIdentifiers":[{},{},{}]}]},"item_9_description_21":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"Lutetiura-177(^<177>Lu) has 176(12.2 %), 384(9.1%) and 497(78.6%)keV beta particle emissions which are suitable for tissue irradiation. Gamma emissions of 113(6.4%) and 208(ll.9%)keV allow gamma imaging. Its physical half-life(6.75 days) is reasonable in terms of shelf life.\nThe preparation of ^<177>Lu-EDTMP(ethylene diamine tetramethylene phosphonic acid) is very simple and this chelate is very stable. In our animal study, ^<177>Lu-EDTMP showed suitable characteristics of rapid blood clearance and selective uptake on bone, which would be necessary for the treatment of palliative pain of bone metastases. The major adverse side effects after administration of ^<177>Lu-EDTMP were platelet and white blood cell count depression. The present study was undertaken to observe the influence of ^<177>Lu-EDTMP on bone marrow. It was clarified that acute radiation death of mouse did not occur by administration of 5MBq, 10MBq or 15MBq of ^<177>Lu-EDTMP, while these dose are likely to cause some myelosuppresion.\nAnd the calculations of radiation dose were performed by utilizing animal distribution data and die MIRD formulations. Estimated radiation dose of bone, bone marrow and whole body were 36.88mGy/3 7MBq, 39.12mGy/37MBq and 5.54mGy/37MBq, respectively.\n^<177>Lu-EDTMP appears to be a useful new compound for the palliation of painful skeletal metastases.","subitem_description_type":"Abstract"},{"subitem_description":"われわれは,転移性骨腫瘍による疼痛の緩和剤として^<177>Lu-EDTMPを研究している。本研究はこの化合物と既に米国などで臨床的に使用されている^<89>SrCl_2、^<153>Sm-EDTMPと比較検討するために行った。\n(1)体内分布:マウスおよびラットによる実験から、^<177>Lu-EDTMPは^<89>SrCl_2に比較して骨取込みはやや少ないが、両者は全体的に非常によく類似した臓器組織取込みを示すことがわかった。ラットの骨組織のオートラジオグラムから、^<177>Lu-EDTMPと^<89>SrCl_2は骨端部に集中し、両化合物は非常によく類似した骨組織取込を示した。^<177>Lu-EDTMPは正常骨に比べ骨折部位へ強い集積が見られた。\n(2)骨髄毒性:マウスへ^<177>Lu-EDTMPの10MBq以下の投与では、赤血球数は変化せず、白血球数および血小板数の一時的な減少があったが、投与48日後には完全に回復した。この時点で骨髄の病理組織学的変化は認められなかった。マウス1匹あたり、^<177>Lu-EDTMPの15MBqの投与でも致死的な急性障害は起こらなかった。この場合も投与しないマウスと同様に体重が増加し、成長した。\n(3)被曝線量:ラットでの実験結果から、^<177>Lu-EDTMP1mCi(37MBq)を人間に投与した場合の被曝線量をMIRD法で計算したところ、全身、骨、骨髄の被曝線量はそれぞれ5.54mGy、36.88mGyおよび39.12mGyであった。この値は^<89>SrCl_2を同量投与した場合よりかなり少なく、^<153>Sm-EDTMPの場合よりやや多かった。\n既に報告した結果および本研究で得られた結果から、^<177>Lu-EDTMP)は転移性骨腫瘍による疼痛の緩和剤として非常に優れた薬剤になると考えられた。","subitem_description_type":"Abstract"}]},"item_9_description_22":{"attribute_name":"内容記述","attribute_value_mlt":[{"subitem_description":"研究課題/領域番号:12670860, 研究期間(年度):2000-2001","subitem_description_type":"Other"},{"subitem_description":"出典：「転移性骨腫瘍による疼痛の緩和と病巣抑制のための放射性医薬品の開発」研究成果報告書　課題番号12670860\n  (KAKEN：科学研究費助成事業データベース（国立情報学研究所）)\n　　　本文データは著者版報告書より作成","subitem_description_type":"Other"}]},"item_9_description_5":{"attribute_name":"提供者所属","attribute_value_mlt":[{"subitem_description":"金沢大学医学系研究科","subitem_description_type":"Other"}]},"item_9_identifier_registration":{"attribute_name":"ID登録","attribute_value_mlt":[{"subitem_identifier_reg_text":"10.24517/00057329","subitem_identifier_reg_type":"JaLC"}]},"item_9_relation_28":{"attribute_name":"関連URI","attribute_value_mlt":[{"subitem_relation_name":[{"subitem_relation_name_text":"https://kaken.nii.ac.jp/search/?qm=20171556"}],"subitem_relation_type_id":{"subitem_relation_type_id_text":"https://kaken.nii.ac.jp/search/?qm=20171556","subitem_relation_type_select":"URI"}},{"subitem_relation_name":[{"subitem_relation_name_text":"https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-12670860/"}],"subitem_relation_type_id":{"subitem_relation_type_id_text":"https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-12670860/","subitem_relation_type_select":"URI"}},{"subitem_relation_name":[{"subitem_relation_name_text":"https://kaken.nii.ac.jp/report/KAKENHI-PROJECT-12670860/126708602001kenkyu_seika_hokoku_gaiyo/"}],"subitem_relation_type_id":{"subitem_relation_type_id_text":"https://kaken.nii.ac.jp/report/KAKENHI-PROJECT-12670860/126708602001kenkyu_seika_hokoku_gaiyo/","subitem_relation_type_select":"URI"}}]},"item_9_version_type_25":{"attribute_name":"著者版フラグ","attribute_value_mlt":[{"subitem_version_resource":"http://purl.org/coar/version/c_ab4af688f83e57aa","subitem_version_type":"AM"}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2021-05-14"}],"displaytype":"detail","filename":"ME-PR-TAKAYAMA-T-kaken 2002-44p.pdf","filesize":[{"value":"3.0 MB"}],"format":"application/pdf","licensetype":"license_11","mimetype":"application/pdf","url":{"label":"ME-PR-TAKAYAMA-T-kaken 2002-44p.pdf","url":"https://kanazawa-u.repo.nii.ac.jp/record/51026/files/ME-PR-TAKAYAMA-T-kaken 2002-44p.pdf"},"version_id":"9ee25331-9d6b-4e21-aeb9-32005927a4bb"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"jpn"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"research report","resourceuri":"http://purl.org/coar/resource_type/c_18ws"}]},"item_title":"転移性骨腫瘍による疼痛の緩和と病巣抑制のための放射性医薬品の開発","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"転移性骨腫瘍による疼痛の緩和と病巣抑制のための放射性医薬品の開発"},{"subitem_title":"Development ofradiopharmaceuticals for palliative therapy of painful osseous metastases","subitem_title_language":"en"}]},"item_type_id":"9","owner":"18","path":["2832"],"pubdate":{"attribute_name":"公開日","attribute_value":"2021-05-14"},"publish_date":"2021-05-14","publish_status":"0","recid":"51026","relation_version_is_last":true,"title":["転移性骨腫瘍による疼痛の緩和と病巣抑制のための放射性医薬品の開発"],"weko_creator_id":"18","weko_shared_id":-1},"updated":"2023-07-27T14:45:13.585588+00:00"}